Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07592767 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

RESvEraTrol in Parkinson's Disease (RESET)

Study acronym: RESET
StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Recruitment opened Start date: Jun 1, 2026 to Sep 17, 2026 · Primary endpoints: details revised at 2 of 4 entries · Study sites: 0 to 1 · 2 more Show 5 more changesShow less
    • Start date: Jun 1, 2026 to Sep 17, 2026
    • Primary endpoints: details revised at 2 of 4 entries
    • Study sites: 0 to 1
    • Eligibility criteria expanded, about 20 words
    • Secondary endpoints: details revised at 2 of 3 entries
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is an exploratory phase 2a study to investigate two doses of resveratrol (JotrolTM) vs placebo in individuals diagnosed with Parkinson's Disease (PD). Participants (n=30) will be randomized 1:1:1 into 3 groups and will receive oral JotrolTM vs placebo. Study drug will be titrated to reach a final maximal dose per group and will be administered orally once daily (QD) for 3 months. The study will primarily evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics (PK/PD) of JotrolTM.
Trial Details
NCT Number NCT07592767
Lead Sponsor Georgetown University
Collaborators: Jupiter Neuroscience Inc., Medstar Health Research Institute
Conditions Parkinson's Disease
Enrollment 30 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov